Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Feb 26;64(1):e22.
doi: 10.1192/j.eurpsy.2021.12.

Chronic obstructive pulmonary disease in severe mental illness: A timely diagnosis to advance the process of quitting smoking

Affiliations
Randomized Controlled Trial

Chronic obstructive pulmonary disease in severe mental illness: A timely diagnosis to advance the process of quitting smoking

M J Jaen-Moreno et al. Eur Psychiatry. .

Abstract

Background: This study has two main objectives: to describe the prevalence of undetected chronic obstructive pulmonary disease (COPD) in a clinical sample of smokers with severe mental illness (SMI), and to assess the value of the Tobacco Intensive Motivational Estimated Risk tool, which informs smokers of their respiratory risk and uses brief text messages to reinforce intervention.

Method: A multicenter, randomized, open-label, and active-controlled clinical trial, with a 12-month follow-up. Outpatients with schizophrenia (SZ) and bipolar disorder were randomized either to the experimental group-studied by spirometry and informed of their calculated lung age and degree of obstruction (if any)-or to the active control group, who followed the 5 A's intervention.

Results: The study sample consisted of 160 patients (71.9% SZ), 78.1% of whom completed the 12-month follow-up. Of the patients who completed the spirometry test, 23.9% showed evidence of COPD (77.8% in moderate or severe stages). TIMER was associated with a significant reduction in tobacco use at week 12 and in the long term, 21.9% of patients reduced consumption and 14.6% at least halved it. At week 48, six patients (7.3%) allocated to the experimental group achieved the seven-day smoking abstinence confirmed by CO (primary outcome in terms of efficacy), compared to three (3.8%) in the control group.

Conclusion: In this clinical pilot trial, one in four outpatients with an SMI who smoked had undiagnosed COPD. An intensive intervention tool favors the early detection of COPD and maintains its efficacy to quit smoking, compared with the standard 5 A's intervention.

Keywords: COPD; bipolar disorder; early detection; schizophrenia; smoking.

PubMed Disclaimer

Conflict of interest statement

Vicent Balanzá-Martínez has received grants and served as consultant, advisor, or continuing medical education (CME) speaker during the last 5 years for the following entities: Angelini Spain, Angelini Portugal, Bristol-Myers-Squibb, Ferrer, Janssen, Juste, Lundbeck, Nutrición Médica, and Otsuka. He acknowledges the national grant PI16/01770 from the Instituto de Salud Carlos III, ISCIII (The PROBILIFE study).

Luis Gutiérrez-Rojas has been speaker for and advisory board member of Bristol-Myers Squibb, Janssen-Cilag, Astra-Zeneca, Rovi, Lundbeck, Otsuka, GSK, and Pfizer.

José Ángel Alcalá during the last 5 years, has received grants and served as

consultant, advisor, or CME speaker for the following entities: Adamed,

Angelini, Casen Recordati, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, and Servier.

Julio Bobes has received research grants and served as consultant, advisor, or speaker within de last 5 years for: AB-Biotics, Acadia Pharmaceuticals, Alkermes, Allergan, Ambrosseti-Angelini, Biogen, Casen Recordati, D&A Pharma, Exeltis, Gilead, Indivior, GW Pharmaceuticals, Janssen-Cilag, Jazz Pharmaceuticals, Lundbeck, Mundipharma, Newron, Otsuka, Pfizer, Roche, Sage Therapeutics, Servier, Schwabe Farma Ibérica, Shire, Takeda, research funding from the Spanish Ministry of Economy and Competitiveness—Centro de Investigación Biomedica en Red area de Salud Mental (CIBERSAM) and Instituto de Salud Carlos III-, Spanish Ministry of Health, Social Services and Equality—Plan Nacional sobre Drogas- and the 7th Framework Program of the European Union.

All other researchers report no biomedical financial interests or potential conflicts of interests.

Figures

Figure 1.
Figure 1.
Flow diagram in the study design. Patient disposition.
Figure 2.
Figure 2.
Effectiveness of the TIMER tool on smokers with an SMI.

Similar articles

Cited by

References

    1. Chesney E, Goodwind GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. 2014;13:153–160. - PMC - PubMed
    1. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72:334–341. doi: 10.1001/jamapsychiatry.2014.2502. - DOI - PMC - PubMed
    1. Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4:295–301. doi: 10.1016/S2215-0366(17)30078-0. - DOI - PubMed
    1. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen DAN, Asai I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10:52–77. doi: 10.1002/j.2051-5545.2011.tb00014.x. - DOI - PMC - PubMed
    1. Crump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry. 2013;70:931–939. doi: 10.1001/jamapsychiatry.2013.1394. - DOI - PubMed

Publication types

MeSH terms